Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

17.86 UNCHANGED

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

March 03, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

January 30, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Preview: Takeda Pharmaceutical's Earnings ↗

October 30, 2024

Via Benzinga

Earnings Scheduled For January 30, 2025 ↗

January 30, 2025

Via Benzinga

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

January 30, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights ↗

January 28, 2025

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

Via Benzinga

FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch ↗

January 15, 2025

The U.S. Food and Drug Administration announced a ban on Red No. 3, an artificial food coloring linked to cancer in animal studies, effective Jan. 15, 2027.

Via Benzinga

Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency ↗

December 27, 2024

Takeda's HYQVIA receives approval in Japan for treating immunodeficiencies, offering a more convenient, less frequent subcutaneous infusion option.

Via Benzinga

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

December 27, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases ↗

December 18, 2024

Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets.

Via Benzinga

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

December 12, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

December 12, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst ↗

December 03, 2024

Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in myelodysplastic syndromes.

Via Benzinga

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

December 03, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

November 21, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients ↗

November 14, 2024

AC Immune reports interim results from Phase 2 trial of ACI-7104.056 active immunotherapy for early Parkinson's disease.

Via Benzinga

Urgency, Debate Mark COP29 As Leaders Push For Carbon Market Rules, Worry About Trump ↗

November 12, 2024

Global leaders gather at COP29 to address climate change, carbon market mechanisms, and climate finance. Urgency and controversy at a fossil fuel reliant host country, but focus on establishing rules...

Via Benzinga

Topics Climate Change

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

October 31, 2024

— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer —

From HUTCHMED (China) Limited

Via GlobeNewswire

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

October 31, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

October 24, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside ↗

October 17, 2024

HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers...

Via Benzinga

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization ↗

October 04, 2024

Johnson & Johnson has discontinued its Phase 2 study of mosnodenvir, an investigational antiviral candidate for dengue prevention, as part of a strategic shift in its R&D portfolio. Final efficacy data...

Via Benzinga

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

September 24, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

September 24, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

September 20, 2024

Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment.

Via MarketBeat

Topics Economy

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

September 19, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

September 18, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines ↗

September 10, 2024

Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential.

Via Benzinga

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗

September 09, 2024

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant...

Via Benzinga

Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production ↗

September 06, 2024

Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.